This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Alan L. Hillman, MD, MBA; Bernard S. Bloom, PhD
The University of Pennsylvania Philadelphia

JAMA. 1991;265(5):593.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

We commend Edelson et al¹ on a thoughtful economic analysis of misoprostol, parts of which extend and corroborate our earlier work.² We agree that the most robust science is produced when different investigators approach a question in different ways and come to similar conclusions, which is indeed the case with portions of our two studies.³

There is one published, randomized, controlled clinical trial of misoprostol for prophylaxis of gastric ulcer, in which all patients had multiple endoscopies.⁴ In this 3-month trial, all of the several hundred patients with osteoarthritis had abdominal pain attributed to use of nonsteroidal anti-inflammatory drugs (NSAIDs) (but no gastric ulcer on endoscopy on entry to the study). The statements of Edelson et al about our interpretation of these data are incorrect. We calculated the relative risk of gastric ulcer in patients receiving misoprostol compared with the control group to . . . [Full Text PDF of this Article]

Footnotes
Edited by Drummond Rennie, MD, Deputy Editor (West), and Don Riesenberg, MD, Senior Editor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?